These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19804705)

  • 1. [Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement].
    Bouée S; Zufferey P; Fagnani F
    Therapie; 2009; 64(4):249-57. PubMed ID: 19804705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
    Omel'ianovskiĭ VV; Zagorodniĭ NV; Margieva AV; Tsfasman FM
    Khirurgiia (Mosk); 2010; (5):72-81. PubMed ID: 20568660
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
    Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
    Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
    Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
    Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
    Plumb JM; Clemens A; Monz BU
    Pharmacoeconomics; 2010; 28(9):781-2; author reply 782-4, 784-5. PubMed ID: 20824908
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
    Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
    Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
    Drug Ther Bull; 2009 Oct; 47(10):116-20. PubMed ID: 19809086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran versus enoxaparin after total hip replacement.
    Martins HS; Scalabrini-Neto A; Velasco IT
    Lancet; 2007 Dec; 370(9604):2002-3; author reply 2003-4. PubMed ID: 18083399
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.